Previous 10 | Next 10 |
2023-11-10 14:16:55 ET More on Moleculin Biotech Seeking Alpha’s Quant Rating on Moleculin Biotech Historical earnings data for Moleculin Biotech Financial information for Moleculin Biotech For further details see: Moleculin Biotech Q3 2023 Earning...
2023-11-10 10:37:05 ET Major earnings expected before the bell on Monday include: Auxly Cannabis Group ( OTCQB:CBWTF ) Capital Product Partners ( CPLP ) Sundial Growers ( SNDL ) Tower Semiconductor ( TSEM ) Tyson Foods ( TSN ) For further deta...
Histogen Inc. (HSTO) is expected to report for Q3 2023 News Corporation (NWSA) is expected to report $0.13 for Q1 2024 TORM plc (TRMD) is expected to report for Q3 2023 Blink Charging Co. (BLNK) is expected to report $-0.47 for Q3 2023 Nuvalent Inc. (NUVL) is expected to report $-...
Moleculin Biotech Inc. (MBRX) is expected to report $-0.2 for Q3 2023
Moleculin to Report Third Quarter Financial Results on November 13, 2023 and Host Conference Call and Webcast PR Newswire HOUSTON , Nov. 7, 2023 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmace...
Moleculin Presents Positive Preliminary Efficacy Findings from Phase 1B/2 Clinical Trial Demonstrating 64% Stable Disease Rate Through Two Cycles of Annamycin for the Treatment of Soft Tissue Sarcomas (STS) Lung Metastases PR Newswire – Poster Presented at the 2023 Conn...
2023-10-24 07:45:53 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips We’re starting off Tuesday with a breakdown of the biggest pre-market stock movers investors will want to know about! Moving stocks this morning are a delisting notice, earnings resu...
Moleculin to Participate in the Virtual Investor Ask the CEO Conference PR Newswire Live video webcast with Walter Klemp, CEO and Jonathan Foster , Executive VP and CFO of Moleculin on Tuesday, October 25 th at 12:00 PM ET HOUSTON , Oct. ...
Moleculin Doses First Subjects in Phase 2 Portion of Clinical Trial Evaluating Annamycin in Combination with Cytarabine (Ara-C) for the Treatment of Acute Myeloid Leukemia (AML) PR Newswire – Phase 1B portion of Phase 1B /2 study demonstrated preliminary CR/...
2023-09-28 07:25:40 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips We’re checking out the biggest pre-market stock movers on Friday with a dive into all of the latest market stories! Moving stocks this morning are clinical trials, new partnerships, ...
News, Short Squeeze, Breakout and More Instantly...
Moleculin Biotech Inc. Company Name:
MBRX Stock Symbol:
NASDAQ Market:
Moleculin Biotech Inc. Website:
2024-06-17 10:10:00 ET June 17, 2024 (Investorideas.com Newswire) Investorideas.com , a go-to investing platform releases the first of a two-part series looking at developments for the treatment of blood cancers. Today's snapshot focuses in on acute myeloid leukemia (AML) and the compan...
Moleculin Announces Additional Positive Preliminary Interim Data from AML Clinical Trial PR Newswire – 89% of CRc's were subjects with "poor prognosis" cytogenetics and/or mutations – Current median durability of response (mDOR) of CRc's = 6 months and in...
Moleculin to Present at the Virtual Investor Pitch Conference PR Newswire Live video webcast on Tuesday, June 18 th at 3:00 PM ET HOUSTON , June 12, 2024 /PRNewswire/ -- Moleculin Biotech, Inc. , (Nasdaq: MBRX) ("Moleculin" or the "Company...